Susan R Rheingold MD
Associate Professor, Pediatrics, Perelman School of Medicine
Join to View Full Profile
3401 Civic Center BlvdChildren's Hospital Of Philadelphia - Hem/OncPhiladelphia, PA 19104
Phone+1 215-590-3535
Fax+1 215-590-3992
Dr. Rheingold is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Susan Rheingold, based in Philadelphia, PA, specializes in Pediatric Hematology & Oncology, particularly leukemia. She trained at Johns Hopkins University and Children's Hospital of Philadelphia after graduating from the Perelman School of Medicine at the University of Pennsylvania. Dr. Rheingold has numerous published works in well-respected medical journals and has been cited by other publications multiple times. She has led a range of clinical trials exploring treatments for B-Lymphoblastic Leukemia and Lymphoblastic Lymphoma, and has been recognized for her work through awards like America's Top Doctors and Philadelphia Magazine's top doctor selection.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1996 - 1999
Johns Hopkins UniversityResidency, Pediatrics, 1992 - 1995
Perelman School of Medicine at the University of PennsylvaniaClass of 1992
Certifications & Licensure
FL State Medical License 2021 - Present
VA State Medical License 2021 - 2028
DE State Medical License 2022 - 2027
MD State Medical License 2021 - 2027
NC State Medical License 2021 - 2027
NJ State Medical License 2018 - 2027
PA State Medical License 1995 - 2026
American Board of Pediatrics Pediatric Hematology-Oncology- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- Philadelphia Magazine Castle Connolly, 2005, 2007-2008, 2010, 2013-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
Clinical Trials
- Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors Start of enrollment: 2002 Nov 01
- Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma Start of enrollment: 2003 Jan 01
- Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma Start of enrollment: 2010 May 01
Publications & Presentations
PubMed
- CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review.Alexander W Rankin, Regina M Myers, Adam J Lamble, Emily M Hsieh, Hari Sankaran
Blood Advances. 2026-02-17 - The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Liora Schultz, Kevin McNerney, Adam J Lamble, Friso G Calkoen, Andre Baruchel
Nature Reviews. Clinical Oncology. 2026-01-23 - Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.Regina M Myers, Yimei Li, Hongyan Liu, Sarah Mumanachit, Lei Wang
Haematologica. 2025-11-27
Journal Articles
- Inotuzumab Ozogamicin in Pediatric Patients with relapsed/refractory Acute Lymphoblastic LeukemiaDeepa Bhojwani, Constance Yuan, Jennifer L McNeer, Mignon L Loh, Vilmarie Rodriguez, Susan R Rheingold, Elizabeth A Raetz, Nature
- Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin LymphomaStephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood
Abstracts/Posters
- A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...Susan R. Rheingold, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell TherapySusan R. Rheingold, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) study.2019 ASCO Annual Meeting - 6/1/2019
- Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clini...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Substantial Progress Made Against Childhood Cancers, Report SaysDecember 5th, 2025- Tribeca Film Festival to Debut Documentary Tracing the Path to Penn Medicine and Children’s Hospital of Philadelphia’s Transformative, Personalized Cancer TherapyJune 9th, 2022
Allterum Therapeutics Completes Series Seed Offering, Builds Team with Addition of Philip Breitfeld as Chief Medical OfficerDecember 17th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
